QOP
ALXN

Quinn Opportunity Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Quinn Opportunity Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-133,511
Closed -$20.4M – 258
2021
Q1 		$20.4M Buy
133,511
+36,511
+38% +$5.65M 1.29% 22
2020
Q4 		$15.2M Buy
+97,000
New +$12.5M 1.29% 17
2017
Q4 		– Sell
-1,500
Closed -$210K – 216
2017
Q3 		$210K Sell
1,500
-1,500
-50% -$204K 0.03% 191
2017
Q2 		$365K Buy
+3,000
New +$349K 0.06% 126

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Quinn Opportunity Partners's ALXN Position: Q2 2021 in Review

Quinn Opportunity Partners sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 133,511 shares — an estimated $20.4M sold.

Quinn Opportunity Partners first reported a position in ALXN in Q2 2017 and held it in 4 quarters. The position peaked at $20.4M in Q1 2021. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Quinn Opportunity Partners reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Quinn Opportunity Partners sold 133,511 Alexion Pharmaceuticals shares in Q2 2021, an estimated $20.4M.
  • Quinn Opportunity Partners first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 4 quarters.
  • Quinn Opportunity Partners's Alexion Pharmaceuticals position peaked at $20.4M in Q1 2021.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Quinn Opportunity Partners's 13F filing for Q2 2021, filed 16 Aug 2021.